Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05065970 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
A Phase 2 study, sponsored by HI-Bio, A Biogen Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT05065970 is a Phase 2 study that has completed, run by HI-Bio, A Biogen Company. The registered enrollment target is 54 participants.
The verdict
NCT05065970, a Phase 2 study, has completed, sponsored by HI-Bio, A Biogen Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
Interventions
- OTHER Placebo
- DRUG Felzartamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-08-31 |
| Est. Completion | 2024-05-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05065970
The ClinicalTrials.gov registry entry for NCT05065970 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HI-Bio, A Biogen Company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05065970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05065970 about?
NCT05065970 is a clinical study titled "Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy". Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
What is the current status of trial NCT05065970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2021-08-31. Estimated completion is 2024-05-06.
What interventions are being tested in trial NCT05065970?
The interventions under investigation include: Placebo (OTHER), Felzartamab (DRUG).
Who is sponsoring clinical trial NCT05065970?
This trial is sponsored by HI-Bio, A Biogen Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.